Search results
PROMOTED
Start date:
Jan 21, 2026
Pacemaker implantation remains one of the most common complications after TAVI. In this webinar, chaired by Prof Rafal Dworakowski (Abbott APAC Medical Affairs Director, Singapore, SG) and Dr Simon Lam (Queen Mary Hospital, Hong Kong, HK), leading specialists will focus on the anatomy of the conduction system anatomy, highlight key pre-procedural planning considerations, and share proven…
View more
Added:
1 month ago
Discover why tricuspid regurgitation aetiology matters for patient outcomes and intervention strategies with Prof Denisa MuraruThis presentation, part of a comprehensive series on complex cases in interventional cardiology, explores how understanding TR mechanisms directly impacts diagnosis, treatment selection, and clinical prognosis.Prof Muraru addresses the critical heterogeneity in TR…
View more
Added:
2 months ago
PCR London Valves 2025 - Dr Vlasis Ninios (Interbalkan European Medical Center, GR) discusses one-year outcomes from the AltaValve Early Feasibility Study, evaluating a novel atrial fixation system for transcatheter mitral valve replacement in patients with severe mitral regurgitation.This prospective, single-arm, multicenter study enrolled high surgical risk patients with moderate to severe or…
View more
Added:
3 months ago
TCT 25 - Dr Raj Makkar (Cedars-Sinai Medical Center, US) joins us to discuss the findings on the EVOQUE Valve (Edwards Lifesciences) drawing from data in the STS/ACC Transcatheter Valve Therapy Registry.The study evaluated procedural success rates, in-hospital complications, and 30-day clinical outcomes in patients undergoing transcatheter tricuspid valve replacement for severe tricuspid…
View more
Added:
7 months ago
New York Valves 2025 - Echocardiographic outcomes from the TRISCEND II substudy reinforce the effectiveness of TTVR compared to medical therapy alone at one year post transcatheter tricuspid valve replacement (TTVR).Dr Paul Grayburn (Baylor Scott and White Research Institute, Dallas, US) joins us to discuss echocardiographic outcomes one year post TTVR from the TRISCEND II substudy which…
View more
Added:
6 months ago
Explore the challenges and outcomes of TAVI in bicuspid aortic stenosis with Prof Ole De Backer (Rigshospitalet, Copenhagen, Denmark).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, examines the unique anatomical considerations and clinical evidence when treating bicuspid valve disease with transcatheter techniques.Prof De Backer addresses…
View more
Added:
8 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Added:
11 months ago
CRT 25 - Two-year outcomes of the Prevail paclitaxel-coated balloon show no difference in clinical outcomes compared to other drug-coated balloons (DCBs), suggesting the Prevail DCB is as effective and safe as other contemporary DCB's in a real-world setting. The Prevail DCB was also associated with lower rates of myocardial infarction in the sub-group analysis of patients who also underwent…
View more
Added:
7 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings…
View more
Added:
11 months ago
CRT 25 - Safety and effectiveness outcomes of the Agent drug-coated balloon (DCB) for the treatment of in-stent restenosis show a major reduction in target lesion failure, including cardiac death, myocardial infarction and target lesion revascularization, compared to balloon angioplasty. The Agent DCB also caused a significant reduction in all target lesion events in comparison with the control…
View more